-

AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more info, visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

AbCellera Biologics Inc.

NASDAQ:ABCL

Release Versions
$Cashtags

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
More News From AbCellera Biologics Inc.

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Stephen Quake to its Board of Directors...

AbCellera Reports Q3 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q3 2025 Business Results...

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025...
Back to Newsroom